| HOME >> BIOLOGY >> TECHNOLOGY |
Retained earnings 2,554,004 2,952,343
Accumulated other comprehensive income 743,696 460,020
Total shareholders' equity 14,989,049 9,747,230
Total liabilities and shareholders'
equity $17,801,527 $12,246,974
SKYSTAR BIO-PHARMACEUTICAL COMPANY AND SUBSIDIARY CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND OTHER COMPREHENSIVE INCOME
FOR THE SIX MONTHS AND THREE MONTHS ENDED JUNE 30, 2007 AND 2006
Three months ended Six months ended
June 30 June 30
2007 2006 2007 2006
Unaudited Unaudited Unaudited Unaudited
Revenue $3,374,459 $2,762,247 $4,742,269 $3,757,435
Cost Of Sales 1,411,291 1,506,295 2,108,326 2,026,734
Gross Profit 1,963,168 1,255,952 2,633,943 1,730,701
Research And
Development Costs 75,225 85,747 106,881 105,086
Amortization Of Deferred
Compensation 101,375 341,145 462,274 341,145
Selling Expenses 148,139 75,574 257,567 143,482
General And Administrative
Expenses 405,071 104,835 721,622 311,072
Income From Operations 1,233,358 648,651 1,085,599 829,916
Other Income (Expenses)
Other income(expense) (148,385) (1,014) (141,226) (1,230)
Interest expense (703,019) - (866,515) -
Income Before Provision
For Income Taxes 381,954 647,637 77,859 828,686
Provision For Income Taxes 233,643 164,294 300,267 191
'/>"/>
SOURCE Skystar Bio-Pharmaceutical Co.![]() Copyright©2007 PR Newswire. |